The startup develops biological therapeutics utilizing Chemokine Analogue inhibitors and G-Protein Coupled Receptor modulation to create treatments for serious global health issues. Their focus on enhancing binding affinity and pharmacological control addresses the significant unmet medical needs in therapeutic efficacy.
Funding
$44.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Approximately 85% of all G protein-coupled receptors (GPCRs) remain undrugged, despite their role in diverse physiological and pathological processes. Traditional drug discovery and development methods face limitations in effectively targeting these metabolic GPCRs. This leaves a significant unmet need for novel therapeutics that can modulate GPCR-associated pathways.
Solution
Orion Biotechnology is developing next-generation therapeutics that target previously undruggable GPCRs for obesity and metabolic disorders. The company's PROcisionXTM platform enables the design of precision-engineered analogs of natural ligands, optimizing potency, binding affinity, and pharmacological control. This platform streamlines phage display, multiplex chemical synthesis, and structure-activity matrix evaluation to accelerate the discovery process. Orion's portfolio includes candidates against GPR75, GIPR, Ghrelin, and Amylin, with lead assets demonstrating efficacy in preclinical evaluations. The company's approach aims to overcome the limitations of traditional GPCR drug discovery, providing opportunities for first-in-class therapeutics.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for obesity, metabolic disorders, and other GPCR-related diseases.
Features
- PROcisionXTM platform for efficient GPCR drug discovery, from target identification to optimized lead in under 6 months
- Streamlined phage display enabling screening of millions of peptide and small protein analogs directly on cells expressing the targeted receptor
- Proprietary multiplex chemical synthesis technology for rapid parallel production of candidate analogs
- In-depth evaluation of structurally related peptide and small protein analog libraries in cell-based assays, generating a structure-activity matrix
- In silico and lab-based approaches for lead optimization, including potency improvement and fine-tuning of signaling activity
- Portfolio of next-generation GPCR-targeted therapeutics for obesity and metabolic disorders
- Developing candidates against GPR75, GIPR, Ghrelin, and Amylin